Mectizan Donation Program | Local power. Global Change.
MERCK A program at The Task Force for Global Health
Switch to French site

Overview

Established in 1987 by Merck & Co., Inc., Kenilworth, N.J., U.S.A.,* the Mectizan Donation Program (MDP) is the longest-running drug donation program for Neglected Tropical Diseases (NTDs).

The vision of the Mectizan Donation Program (MDP) is to work with partners to achieve a future free of onchocerciasis (river blindness) and lymphatic filariasis (LF or elephantiasis).

The MDP secretariat is housed at the Task Force for Global Health. The Program was established by Merck to provide medical, technical, and administrative oversight of the donation of its drug Mectizan to control river blindness (also known as onchocerciasis) in Latin America, Africa, and Yemen. Merck’s commitment is “as much as needed, for as long as needed.”

In 1998, Merck expanded the program to include Mectizan for the elimination of lymphatic filariasis (LF – also known as elephantiasis or “big foot disease”) in Yemen and in countries in Africa where river blindness and LF are co-endemic.

In countries where river blindness and LF are co-endemic, the World Health Organization (WHO) recommends a single annual dose of Mectizan co-administered with a dose of albendazole, donated by GlaxoSmithKline (GSK), to be administered for at least five years to reduce transmission of the disease to the point where it is no longer sustainable. This reduction in transmission is the first pillar of an LF elimination program. Morbidity management and disability prevention (MMDP) makes up the second pillar.

Currently, MDP approves approximately 300 million treatments annually for river blindness and LF, where they are administered by community-directed distributors. The donation and distribution of Mectizan and albendazole involve a complex global partnership of WHO and its regional offices, governmental and nongovernmental organizations, local communities, donors, research institutions, academia, and the private sector.

In 2017, in support of new WHO guidelines, Merck committed an additional 100 million treatments annually, expanding the Program into select countries worldwide where the co-administration of ivermectin, diethylcarbamazine (DEC), and albendazole (IDA or “triple therapy”) will help accelerate elimination of LF in countries where onchocerciasis is not endemic.

The potential to eliminate both diseases is not only feasible but increasingly within reach.

*Merck & Co., Inc., Kenilworth, N.J., U.S.A., is known as MSD outside of the United States and Canada.